141 related articles for article (PubMed ID: 32531992)
1. Pazopanib and Trametinib as a Synergistic Strategy against Osteosarcoma: Preclinical Activity and Molecular Insights.
Chiabotto G; Grignani G; Todorovic M; Martin V; Centomo ML; Prola E; Giordano G; Merlini A; Miglio U; Berrino E; Napione L; Isella C; Capozzi F; Basiricò M; Marsero C; Gerardi I; Venesio T; Sangiolo D; Aglietta M; D'Ambrosio L; Pignochino Y
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32531992
[TBL] [Abstract][Full Text] [Related]
2. Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer.
Ball DW; Jin N; Xue P; Bhan S; Ahmed SR; Rosen DM; Schayowitz A; Clark DP; Nelkin BD
Oncol Rep; 2015 Nov; 34(5):2319-24. PubMed ID: 26324075
[TBL] [Abstract][Full Text] [Related]
3. The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.
Pignochino Y; Dell'Aglio C; Basiricò M; Capozzi F; Soster M; Marchiò S; Bruno S; Gammaitoni L; Sangiolo D; Torchiaro E; D'Ambrosio L; Fagioli F; Ferrari S; Alberghini M; Picci P; Aglietta M; Grignani G
Clin Cancer Res; 2013 Apr; 19(8):2117-31. PubMed ID: 23434734
[TBL] [Abstract][Full Text] [Related]
4. MEK inhibition preferentially suppresses anchorage-independent growth in osteosarcoma cells and decreases tumors in vivo.
Shimizu T; Kimura K; Sugihara E; Yamaguchi-Iwai S; Nobusue H; Sampetrean O; Otsuki Y; Fukuchi Y; Saitoh K; Kato K; Soga T; Muto A; Saya H
J Orthop Res; 2021 Dec; 39(12):2732-2743. PubMed ID: 33751653
[TBL] [Abstract][Full Text] [Related]
5. Pazopanib, a novel multi-kinase inhibitor, shows potent antitumor activity in colon cancer through PUMA-mediated apoptosis.
Zhang L; Wang H; Li W; Zhong J; Yu R; Huang X; Wang H; Tan Z; Wang J; Zhang Y
Oncotarget; 2017 Jan; 8(2):3289-3303. PubMed ID: 27924057
[TBL] [Abstract][Full Text] [Related]
6. Activation of ERK1/2 Causes Pazopanib Resistance via Downregulation of DUSP6 in Synovial Sarcoma Cells.
Yokoyama N; Matsunobu T; Matsumoto Y; Fukushi JI; Endo M; Hatano M; Nabeshima A; Fukushima S; Okada S; Iwamoto Y
Sci Rep; 2017 Mar; 7():45332. PubMed ID: 28350009
[TBL] [Abstract][Full Text] [Related]
7. Highly-expressed P2X7 receptor promotes growth and metastasis of human HOS/MNNG osteosarcoma cells via PI3K/Akt/GSK3β/β-catenin and mTOR/HIF1α/VEGF signaling.
Zhang Y; Cheng H; Li W; Wu H; Yang Y
Int J Cancer; 2019 Aug; 145(4):1068-1082. PubMed ID: 30761524
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of MEK suppresses hepatocellular carcinoma growth through independent MYC and BIM regulation.
Zhou X; Zhu A; Gu X; Xie G
Cell Oncol (Dordr); 2019 Jun; 42(3):369-380. PubMed ID: 30788663
[TBL] [Abstract][Full Text] [Related]
9. Reversion effects of curcumin on multidrug resistance of MNNG/HOS human osteosarcoma cells in vitro and in vivo through regulation of P-glycoprotein.
Si M; Zhao J; Li X; Tian JG; Li YG; Li JM
Chin Med J (Engl); 2013 Nov; 126(21):4116-23. PubMed ID: 24229684
[TBL] [Abstract][Full Text] [Related]
10. Overactive IGF1/Insulin Receptors and NRASQ61R Mutation Drive Mechanisms of Resistance to Pazopanib and Define Rational Combination Strategies to Treat Synovial Sarcoma.
Lanzi C; Dal Bo L; Favini E; Tortoreto M; Beretta GL; Arrighetti N; Zaffaroni N; Cassinelli G
Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30909453
[TBL] [Abstract][Full Text] [Related]
11. Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma.
Cavalloni G; Peraldo-Neia C; Varamo C; Chiorino G; Sassi F; Aglietta M; Leone F
Oncotarget; 2016 Aug; 7(32):52354-52363. PubMed ID: 27429047
[TBL] [Abstract][Full Text] [Related]
12. Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines.
Olaussen KA; Commo F; Tailler M; Lacroix L; Vitale I; Raza SQ; Richon C; Dessen P; Lazar V; Soria JC; Kroemer G
Oncogene; 2009 Dec; 28(48):4249-60. PubMed ID: 19749798
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib induces apoptosis and autophagy in osteosarcoma cells through mitogen-activated protein kinase pathway in vitro.
Lou Z; Ren T; Peng X; Sun Y; Jiao G; Lu Q; Zhang S; Lu X; Guo W
J Int Med Res; 2013 Oct; 41(5):1505-19. PubMed ID: 23975859
[TBL] [Abstract][Full Text] [Related]
14. The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo.
Booth L; Roberts JL; Sander C; Lee J; Kirkwood JM; Poklepovic A; Dent P
Oncotarget; 2017 Mar; 8(10):16367-16386. PubMed ID: 28146421
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-12 and interleukin-18 induce indoleamine 2,3-dioxygenase (IDO) activity in human osteosarcoma cell lines independently from interferon-gamma.
Liebau C; Baltzer AW; Schmidt S; Roesel C; Karreman C; Prisack JB; Bojar H; Merk H
Anticancer Res; 2002; 22(2A):931-6. PubMed ID: 12014674
[TBL] [Abstract][Full Text] [Related]
16. A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers.
Kurzrock R; Ball DW; Zahurak ML; Nelkin BD; Subbiah V; Ahmed S; O'Connor A; Karunsena E; Parkinson RM; Bishop JA; Ha Y; Sharma R; Gocke CD; Zinner R; Rudek MA; Sherman SI; Azad NS
Clin Cancer Res; 2019 Sep; 25(18):5475-5484. PubMed ID: 31186313
[TBL] [Abstract][Full Text] [Related]
17. MEK inhibition induces apoptosis in osteosarcoma cells with constitutive ERK1/2 phosphorylation.
Baranski Z; Booij TH; Kuijjer ML; de Jong Y; Cleton-Jansen AM; Price LS; van de Water B; Bovée JV; Hogendoorn PC; Danen EH
Genes Cancer; 2015 Nov; 6(11-12):503-12. PubMed ID: 26807203
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of autophagy-related protein 6, Beclin-1, decreases cell growth, invasion, and metastasis and has a positive effect on chemotherapy-induced cytotoxicity in osteosarcoma cells.
Zhang W; Li Q; Song C; Lao L
Tumour Biol; 2015 Apr; 36(4):2531-9. PubMed ID: 25427639
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
Menendez JA; Vellon L; Colomer R; Lupu R
Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
[TBL] [Abstract][Full Text] [Related]
20. C₁₈H₁₇NO₆ Inhibits Invasion and Migration of Human MNNG Osteosarcoma Cells via the PI3K/AKT Signaling Pathway.
Qu Q; He Z; Jiang Y; Lu D; Long X; Ding Y; Xu B; He X
Med Sci Monit; 2019 Oct; 25():7527-7537. PubMed ID: 31589596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
